Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
PML caused by John Cunningham (JC) virus is a rare but an increasingly recognized entity. With the advent of newer immunomodulatory therapies with monoclonal antibodies, there is an increasing incidence of PML. Initially concern was restricted to patients treated for multiple sclerosis with natalizu...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Neurological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2015/892047 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850223215532572672 |
|---|---|
| author | Michael A. Lane Vijay Renga Andrew R. Pachner Jeffrey A. Cohen |
| author_facet | Michael A. Lane Vijay Renga Andrew R. Pachner Jeffrey A. Cohen |
| author_sort | Michael A. Lane |
| collection | DOAJ |
| description | PML caused by John Cunningham (JC) virus is a rare but an increasingly recognized entity. With the advent of newer immunomodulatory therapies with monoclonal antibodies, there is an increasing incidence of PML. Initially concern was restricted to patients treated for multiple sclerosis with natalizumab but more case reports are being reported during treatment for other conditions like Crohn’s disease and lymphoma with agents such as rituximab. We report the case of a 66-year-old woman who developed PML a year after completion of therapy with rituximab, ibritumomab, and bendamustine. |
| format | Article |
| id | doaj-art-5ded993d672d4e6795b9cf20bd355b72 |
| institution | OA Journals |
| issn | 2090-6668 2090-6676 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Neurological Medicine |
| spelling | doaj-art-5ded993d672d4e6795b9cf20bd355b722025-08-20T02:06:03ZengWileyCase Reports in Neurological Medicine2090-66682090-66762015-01-01201510.1155/2015/892047892047Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab TiuxetanMichael A. Lane0Vijay Renga1Andrew R. Pachner2Jeffrey A. Cohen3Department of Neurology, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03766, USADepartment of Neurology, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03766, USADepartment of Neurology, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03766, USADepartment of Neurology, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03766, USAPML caused by John Cunningham (JC) virus is a rare but an increasingly recognized entity. With the advent of newer immunomodulatory therapies with monoclonal antibodies, there is an increasing incidence of PML. Initially concern was restricted to patients treated for multiple sclerosis with natalizumab but more case reports are being reported during treatment for other conditions like Crohn’s disease and lymphoma with agents such as rituximab. We report the case of a 66-year-old woman who developed PML a year after completion of therapy with rituximab, ibritumomab, and bendamustine.http://dx.doi.org/10.1155/2015/892047 |
| spellingShingle | Michael A. Lane Vijay Renga Andrew R. Pachner Jeffrey A. Cohen Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan Case Reports in Neurological Medicine |
| title | Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan |
| title_full | Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan |
| title_fullStr | Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan |
| title_full_unstemmed | Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan |
| title_short | Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan |
| title_sort | late occurrence of pml in a patient treated for lymphoma with immunomodulatory chemotherapies bendamustine rituximab and ibritumomab tiuxetan |
| url | http://dx.doi.org/10.1155/2015/892047 |
| work_keys_str_mv | AT michaelalane lateoccurrenceofpmlinapatienttreatedforlymphomawithimmunomodulatorychemotherapiesbendamustinerituximabandibritumomabtiuxetan AT vijayrenga lateoccurrenceofpmlinapatienttreatedforlymphomawithimmunomodulatorychemotherapiesbendamustinerituximabandibritumomabtiuxetan AT andrewrpachner lateoccurrenceofpmlinapatienttreatedforlymphomawithimmunomodulatorychemotherapiesbendamustinerituximabandibritumomabtiuxetan AT jeffreyacohen lateoccurrenceofpmlinapatienttreatedforlymphomawithimmunomodulatorychemotherapiesbendamustinerituximabandibritumomabtiuxetan |